Clinical Trials on i-PRF

Total 3276 results

Fundación para la Investigación del Hospital Clínico...

Completed

Intraoperative Air-Test

Patients With ASA Status I-III Scheduled for Surgery

Spain
Sunovion

Completed

Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex (PERSIST)

Bipolar I Disorder

United States, Croatia, Hungary, Poland, Serbia, Argentina, Japan, France, Slovakia, Australia, Russian Federation, Bulgaria, Chile, Czech Republic
Dana-Farber Cancer Institute
MedWaves, Inc

Not yet recruiting

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Lung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung Cancer

United States
Guangdong Provincial People's Hospital

Recruiting

Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection

NSCLC, Stage I | Disease Free Survival | Pulmonary Function Assessment

China
Ivoclar Vivadent AG

Not yet recruiting

Clinical Evaluation of a New Flowable and a New Sculptable Universal Bulk-fill Composite for Direct Restorative Treatment

Class I or II Cavities in Premolars or Molars
AbbVie

Not yet recruiting

Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder (CReW BP-I)

Bipolar I Disorder
China Medical University Hospital
National Science and Technology Council

Recruiting

NMDA Receptor Modulation for the Treatment of Bipolar I Disorder

Bipolar I Disorder

Taiwan
V.A. Nasonova Research Institute of Rheumatology...
AstraZeneca

Not yet recruiting

Evaluation of Type I IFN Level and Disease Activity in SLE Patients

Elevated Level of IFN Type I in SLE Patients
University Hospital, Clermont-Ferrand
Origio A/S

Unknown

Comparison of Vitrification Effect Before or After In Vitro Maturation

Oocytes Vitrified at Prophase-I Stage | Oocytes Matured in Vitro

France
Isofol Medical AB

Completed

Study Evaluating ECG Effects, Safety, Tolerability and Pharmacokinetics of Single Doses of Modufolin (Arfolitixorin) in Healthy Volunteers Tetrahydrofolate in Healthy Male Volunteers

Phase I Study in Healthy Volunteers to Evaluate ECG Effect

Sweden
Statens Serum Institut
European and Developing Countries Clinical Trials Partnership (EDCTP); Ministry...

Completed

HIV-1 Peptide Immunisation of Individuals in West Africa to Prevent Disease (HIV-BIS)

Aids, Cdc Group I

Guinea-Bissau
CES University
University of Michigan; Universidad del Valle, Colombia

Unknown

A Biotype Enhancing Strategy For The Patient Undergoing Accelerated Orthodontics

Thin Gingival Biotype | Class I Malocclusion | Other Periodontal Diseases
State University of New York at Buffalo

Completed

BRIUS Vs FFA Efficiency

Dental Malocclusion | Crowding, Tooth | Angle Class II | Angle Class I

United States
Genzyme, a Sanofi Company

Recruiting

Mucopolysaccharidosis I (MPS I) Registry

Mucopolysaccharidosis I (MPS I)

Croatia, United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Hong Kong, India, Indonesia, Korea, Republic of, Kuwait, Lebanon, Malaysia, Netherlands, Pakistan, Philippines, Poland, Saudi Arabia, Singapore, Slovaki... and more
Cynosure, Inc.

Completed

Skintel Integration Study

Skin Type From I-VI on Non-hair Bearing Skin
Xian Children's Hospital

Completed

Application of I-gel Laryngeal Mask Airway in Pediatric Patients

the Efficacy and Performance of the Pediatric I-gel Mask

China
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Ragweed Pollen Allergoid With Monophosphoryl Lipid A (MPL) Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Grass MATA MPL

Type I Hypersensitivity

United States, Canada, United Kingdom, Austria
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen

Type I Hypersensitivity

United States
Allergy Therapeutics

Completed

Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test

Type I Hypersensitivity

United States
Lexent Bio, Inc.

Terminated

Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"

Neoplasms, Non-hematologic - Stage I-III

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

Bipolar I Disorder

United States, Argentina
Allergy Therapeutics

Completed

Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen

Type I Hypersensitivity

Germany
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Tree (Birch, Hazel, and Alder) Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Efficacy and Safety/Tolerability of Ragweed MATA MPL

Type I Hypersensitivity

Canada, United States
Allergy Therapeutics

Completed

Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen

Type I Hypersensitivity

United States
Allergy Therapeutics

Withdrawn

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

Type I Hypersensitivity

Canada
Allergy Therapeutics

Completed

Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen

Type I Hypersensitivity

Canada
University Hospital, Ghent

Terminated

Nitrous Oxide - Sevoflurane-Remifentanil Interaction

ASA Class I/II Patients Scheduled for Surgery Under General Anesthesia

Belgium
Allergy Therapeutics

Completed

Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing

Type I Hypersensitivity

United States
Herlev Hospital

Unknown

The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons

Interaction Between the GH/IGF-I System and the Immune-system

Denmark
AbbVie

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Depression | Bipolar I Disorder

United States, Puerto Rico, Russian Federation
Ain Shams University

Completed

I-gel Versus Air-Q LMA for Pediatric Patients

Easy Insertion, Complications Ans Suitability of i Gel and Air Q LMA

Egypt
University of British Columbia

Completed

Lurasidone and Cognition in Bipolar I Disorder

Bipolar I Disorder

Canada
University of Pittsburgh
National Alliance for Research on Schizophrenia and Depression

Completed

L-Carnosine for Bipolar I Disorder

Bipolar I Disorder

United States
Vastra Gotaland Region
AstraZeneca

Recruiting

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID)

NSCLC, Stage I

Finland, Norway, Sweden
Sunovion

Completed

This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 (PERSISTExt)

Bipolar I Disorder

United States, Poland, Bulgaria, Japan, Slovakia, Hungary, Russian Federation, Czech Republic, Argentina, Chile, France, Serbia
Eli Lilly and Company

Completed

Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed

Bipolar I Disorder

Japan
Rush University Medical Center
The Ryan Licht Sang Bipolar Foundation

Completed

Using Neuroplasticity-Based Computerized Training to Improve Emotion Regulation in Bipolar Disorder (BRAINS) (BRAINS)

Bipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective Disorder

United States
University of Texas Southwestern Medical Center
National Institute of Mental Health (NIMH); Beth Israel Deaconess Medical Center and other collaborators

Completed

Psychosis and Affective Research Domains and Intermediate Phenotypes (PARDIP)

Bipolar I Disorder, Unspecified, With Psychotic Features | Bipolar I Disorder, Unspecified, Without Psychotic Features

United States
University Hospital Pierre Zobda-Quitman

Terminated

Safety and Efficiency Study of Valproic Acid In HAM/TSP (VALPROHAM)

HTLV-I-Associated Myelopathy
Sanofi

Completed

A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care Setting (HomERT)

Pompe Disease | Mucopolysaccharidosis Type I (MPS I)

Italy
Otsuka Pharmaceutical Development & Commercialization...
Otsuka America Pharmaceutical

Completed

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Bipolar I Disorder

United States
Epividian
ViiV Healthcare

Completed

Charlotte Retention in Care Study

HIV I Infection

United States
Bionor Immuno AS
Celgene Corporation

Completed

Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (REDUC)

HIV I Infection

Denmark
InnoRa GmbH

Terminated

Safety and Tolerance of the Use of InnoCath AB® Hyper-compliant Balloon (HYPER)

Lesions in the Superficial Femoral Artery and/or Popliteal Artery Pars I/II

Germany
Bionor Immuno AS

Completed

Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV

HIV I Infection

Germany, United States, Spain, United Kingdom, Italy
ProgenaBiome

Recruiting

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder

Bipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder Severe

United States
Catalyst Biosciences

Terminated

Screening Study to Identify Patients With Complement Factor I Deficiencies

Previous Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I Deficiency

United States

Clinical Trials on i-PRF

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations